Abstract: The present invention relates to a pharmaceutical cocktail and methods of cancer treatment. In particular, one such cocktail comprises a combination of effective amounts of a lactate transporter inhibitor, a carbonic anhydrase inhibitor, a sodium potassium chloride cofactor (NKCC) transporter inhibitor, a member of the hydroxycinnamate class of drugs or a derivative thereof, and/or an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab in combination with blood vessel occlusion. As most cancers in an untreated state uses both aerobic and anaerobic/glycolytic pathways treatments contemplated herein can affect both metabolic pathways.

Abstract: The present invention relates to a pharmaceutical cocktail and methods of cancer treatment. In particular, one such cocktail comprises a combination of effective amounts of a lactate transporter inhibitor, a carbonic anhydrase inhibitor, a sodium potassium chloride cofactor (NKCC) transporter inhibitor, a member of the hydroxycinnamate class of drugs or a derivative thereof, and/or an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab in combination with blood vessel occlusion. As most cancers in an untreated state uses both aerobic and anaerobic/glycolytic pathways treatments contemplated herein can affect both metabolic pathways.

Abstract: The present invention relates to a pharmaceutical cocktail and methods of treatment involving said cocktail, in particular, a combination of effective amounts of a carbonic anhydrase inhibitor, in combination with effective amounts of an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab for the treatment of cancer. In other embodiments, it relates to compositions and methods of treating cancer involving effective amounts of a carbonic anhydrase inhibitor. Pharmaceutical compositions and methods of treating cancer (eliminating the tumor, shrinking the tumor, prolonging the life of the patient, increasing quality of life by decreasing the grade of adverse events seen with other cancer treatments, and/or preventing/reducing the likelihood of the tumor's metastases) are additional aspects of the present invention.

Abstract: The present invention relates to a pharmaceutical cocktail and methods of treatment involving said cocktail, in particular, a combination of effective amounts of a carbonic anhydrase inhibitor, in combination with effective amounts of an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab for the treatment of cancer. In other embodiments, it relates to compositions and methods of treating cancer involving effective amounts of a carbonic anhydrase inhibitor. Pharmaceutical compositions and methods of treating cancer (eliminating the tumor, shrinking the tumor, prolonging the life of the patient, increasing quality of life by decreasing the grade of adverse events seen with other cancer treatments, and/or preventing/reducing the likelihood of the tumor's metastases) are additional aspects of the present invention.

Abstract: The present invention relates to a pharmaceutical cocktail and methods of treatment involving said cocktail, in particular, a combination of effective amounts of a carbonic anhydrase inhibitor, in combination with effective amounts of an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab for the treatment of cancer. In other embodiments, it relates to compositions and methods of treating cancer involving effective amounts of a carbonic anhydrase inhibitor. Pharmaceutical compositions and methods of treating cancer (eliminating the tumor, shrinking the tumor, prolonging the life of the patient, increasing quality of life by decreasing the grade of adverse events seen with other cancer treatments, and/or preventing/reducing the likelihood of the tumor's metastases) are additional aspects of the present invention.

Abstract: The present invention relates to a pharmaceutical cocktail and methods of cancer treatment. In particular, one such cocktail comprises a combination of effective amounts of a lactate transporter inhibitor, a carbonic anhydrase inhibitor, a sodium potassium chloride cofactor (NKCC) transporter inhibitor, a member of the hydroxycinnamate class of drugs or a derivative thereof, and/or an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab in combination with blood vessel occlusion. As most cancers in an untreated state uses both aerobic and anaerobic/glycolytic pathways treatments contemplated herein can affect both metabolic pathways.

Abstract: The present invention relates to a pharmaceutical cocktail and methods of treatment involving said cocktail, in particular, a combination of effective amounts of a carbonic anhydrase inhibitor, in combination with effective amounts of an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab for the treatment of cancer. In other embodiments, it relates to compositions and methods of treating cancer involving effective amounts of a carbonic anhydrase inhibitor. Pharmaceutical compositions and methods of treating cancer (eliminating the tumor, shrinking the tumor, prolonging the life of the patient, increasing quality of life by decreasing the grade of adverse events seen with other cancer treatments, and/or preventing/reducing the likelihood of the tumor's metastases) are additional aspects of the present invention.

Abstract: A method for detecting abnormal biological tissue includes administering a vasoactive agent and determining the rate of blood flow in a tissue of interest.

Abstract: Safety apparel and/or non-apparel items that filter from the air one or more airborne particles and/or undesired gasses to provide safety to a human and/or non-human from potentially unhealthy airborne particles. The apparel and/or non-apparel item at least partially includes a filter material. The filter material on the apparel and/or non-apparel item has a sufficient size to enable the human and/or non-human to cover the nose, eyes, and/or mouth of the human and/or non-human. The filter material filters at least one airborne particle and/or undesired gas by a mechanical mechanism, an electrical mechanism, and/or a chemical mechanism. The apparel and/or non-apparel item can include at least one visual and/or textural indicator on the apparel and/or non-apparel item to at least partially indicate the location of the filter material on the apparel and/or non-apparel item.

Abstract: Safety apparel and/or non-apparel items that filter from the air one or more airborne particles and/or undesired gases to provide safety to a human and/or non-human from potentially unhealthy airborne particles. The apparel and/or non-apparel item at least partially includes a filter material. The filter material on the apparel and/or non-apparel item has a sufficient size to enable the human and/or non-human to cover the nose, eyes, and/or mouth of the human and/or non-human. The filter material filters at least one airborne particle and/or undesired gas by a mechanical mechanism, an electrical mechanism, and/or a chemical mechanism. The apparel and/or non-apparel item can include at least one visual and/or textural indicator on the apparel and/or non-apparel item to at least partially indicate the location of the filter material on the apparel and/or non-apparel item.

Abstract: Safety apparel and/or non-apparel items that filter from the air one or more airborne particles and/or undesired gasses to provide safety to a human and/or non-human from potentially unhealthy airborne particles. The apparel and/or non-apparel item at least partially includes a filter material. The filter material on the apparel and/or non-apparel item has a sufficient size to enable the human and/or non-human to cover the nose, eyes, and/or mouth of the human and/or non-human. The filter material filters at least one airborne particle and/or undesired gas by a mechanical mechanism, an electrical mechanism, and/or a chemical mechanism. The apparel and/or non-apparel item can include at least one visual and/or textural indicator on the apparel and/or non-apparel item to at least partially indicate the location of the filter material on the apparel and/or non-apparel item.

Abstract: Safety apparel and/or non-apparel items that filter from the air one or more airborne particles and/or undesired gasses to provide safety to a human and/or non-human from potentially unhealthy airborne particles. The apparel and/or non-apparel item at least partially includes a filter material. The filter material on the apparel and/or non-apparel item has a sufficient size to enable the human and/or non-human to cover the nose, eyes, and/or mouth of the human and/or non-human. The filter material filters at least one airborne particle and/or undesired gas by a mechanical mechanism, an electrical mechanism, and/or a chemical mechanism. The apparel and/or non-apparel item can include at least one visual and/or textural indicator on the apparel and/or non-apparel item to at least partially indicate the location of the filter material on the apparel and/or non-apparel item.

Abstract: Provided is a new therapeutic method to treat cancer that combines radiofrequency (RF) ablation and local controlled drug delivery. A preferred method utilizes localized drug delivery of 5-fluorouricil (5-FU) from polyanhydride implants.

Abstract: The present invention relates to drug delivery devices that provide sustained release of a therapeutic agent upon implantation into a patient. In certain embodiments, the devices provide an initial burst release of an agent, followed by sustained release of that agent, or of a different agent. The devices comprise a central core surrounded at least one membrane or coating.

Abstract: A cargo delivery device has coaxial, telescopically interengaged cargo delivery needle, an outer cannulas which are axially and rotatably displaceable relative to one another. The cargo delivery needle has a distal portion provided with a cargo recess for carrying a cargo to a site in a patient.

Abstract: A method and device for generating a forensic skull and soft tissue database used for the on-line facial reconstruction of victims and age progression portrait rendering of missing children through utilization of advance diagnostic radiologic modalities.

Abstract: A biopsy needle has coaxial, telescopically interengaged stylet, inner and outer cannulas which are axially and rotatably displaceable relative to one another. The stylet has a distal portion provided with a cutting recess for severing a biopsy specimen from a site in a patient, and the inner cannula has a distal portion for cutting and capturing the specimen in the recess for removal from the site upon withdrawal of the needle from the patient. The distal portion of the inner cannula is partially cut away to provide an insert recess which supports a semi-circular insert of hemostatic collagen which remains at the site upon removal of the needle to minimize hemorrhagic complications by promoting blood clotting. The insert and the distal portion of the inner cannula have radially outer surfaces of corresponding radius whereby the distal portion of the inner cannula and the insert supported thereon are received within the distal end of the outer cannula prior to use of the needle.

Abstract: A tubular sheath is disclosed which is slidably disposed over a tubular medical device which tubular medical device is positioned at a body tissue access site. The sheath is deposited within a patient to assist in sealing the incision caused by the tubular medical device and inhibit internal and external bleeding. The sheath includes a generally rigid outer coating and an absorbable and expandable inner core, which when positioned, in situ, at the accessed opening of the patient's body part can function as a vascular plug.

Abstract: A biopsy needle has coaxial, telescopically interengaged stylet, inner and outer cannulas which are axially and rotatably displaceable relative to one another. The stylet has a distal portion provided with a cutting recess for severing a biopsy specimen from a site in a patient, and the inner cannula has a distal portion for cutting and capturing the specimen in the recess for removal from the site upon withdrawal of the needle from the patient. The distal portion of the inner cannula is partially cut away to provide an insert recess which supports a semi-circular insert of hemostatic collagen which remains at the site upon removal of the needle to minimize hemorrhagic complications by promoting blood clotting. The insert and the distal portion of the inner cannula have radially outer surfaces of corresponding radius whereby the distal portion of the inner cannula and the insert supported thereon are received within the distal end of the outer cannula prior to use of the needle.

Abstract: An improved, cone shaped puncturing/cutting tip is provided for the inner cannula or alternative, the stylet, of a biopsy needle. The cone shaped tip is defined by a frontal vertex co-incident with the center of the cannula or the stylet and a circular base of diameter about equal that of the cannula or stylet. The surface of the cone shaped tip end includes at least three circumferentially spaced, longitudinally extending cutting vane edges extending from the vertex to the base and is hollowed between adjacent vane cutting edges whereby cutting penetration of said tip to the site is enhanced without significant vertex deflection of the point during penetration.